What makes this more than just a software upgrade is its precision. By scanning image data rather than relying solely on manual patient inputs like age or family history, Mirai identifies early patterns that even trained eyes might miss. And it doesn\u2019t stumble when some patient records are incomplete or inconsistent.<\/p>\n
Why Mirai Outperforms Existing Models<\/h3>\n
Traditional risk tools focus on patient history and demographic data, which limits their predictive range. Mirai<\/strong> processes mammograms directly, picking up on tiny markers invisible to humans. It also works well across different imaging machines and patient groups, maintaining accuracy regardless of equipment or background.<\/p>\n Importantly, Mirai performs consistently across racial lines. Studies show that it\u2019s just as accurate for Black women as it is for white women\u2014an important step toward addressing breast cancer disparities. Black women in the U.S. have a 43% higher death rate from breast cancer. Tools like Mirai could help reduce that gap by spotting risks sooner and enabling faster care<\/strong>.<\/p>\n Mirai isn\u2019t just a lab experiment\u2014it\u2019s caught the attention of major voices. Indian businessman Anand Mahindra<\/strong> praised the model\u2019s potential, noting how quickly AI is proving its value in healthcare. \u201cIf this is accurate,\u201d he said on X, \u201cthen AI is going to be of significantly more value to us than we imagined.\u201d<\/p>\n This isn’t hype. AI models like Mirai allow for proactive care plans tailored to individual patients. Dr. Vineet Nakra<\/strong>, a radiation oncologist at Max Super Speciality Hospital, says these systems speed up diagnosis and help create more effective treatments. The result? Better survival rates and less invasive interventions.<\/strong><\/p>\n MIT isn\u2019t alone in this work. Researchers at Duke University<\/strong> are also pushing AI\u2019s potential in breast cancer prediction. Their models\u2014designed to be interpretable, not just accurate\u2014also outperform traditional tools. In a study published in Radiology<\/em>, Duke\u2019s AI systems provided stronger predictions over a five-year window, using the same types of imaging data.<\/p>\n This growing body of research shows a clear trend. AI is moving from theory to application in oncology,<\/strong> reshaping everything from detection to drug design.<\/p>\n Still, no system is perfect. Integrating AI like Mirai into everyday clinical settings isn\u2019t plug-and-play. Health systems must balance algorithmic accuracy with privacy protections, and regulators need to build frameworks for safe adoption.<\/p>\n Even the best models, including Mirai, must be tested and calibrated across global populations before they\u2019re embedded in national screening programs. As explained in Science Translational Medicine<\/em><\/strong>, models must be adaptable because real-world data isn\u2019t always complete or standardized.<\/p>\n Mirai is more than a promising algorithm\u2014it signals where medicine is going. With AI tools capable of seeing years ahead<\/strong>, early detection becomes more than just a goal\u2014it becomes standard practice. Mortality rates could drop. Treatments could be more targeted. Screenings could be smarter, not just more frequent.<\/p>\n For those watching AI\u2019s role in healthcare, this is a turning point. With each breakthrough, we\u2019re not just diagnosing disease earlier\u2014we\u2019re rewriting what early diagnosis means.<\/p>","protected":false},"excerpt":{"rendered":" Predicting Breast Cancer Years Before It Strikes together with the Jameel Clinic, has introduced a deep learning model that could change how we detect breast cancer. Known as Mirai, this AI tool analyzes mammograms to predict risk up to five years in advance\u2014outperforming existing clinical models. What makes this more than just a software upgrade […]<\/p>\n","protected":false},"author":1,"featured_media":4108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[299,300,301],"class_list":["post-3948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-ai-detects-breast-cancer","tag-mirai-ai","tag-mits-computer-science-and-artificial-intelligence-laboratory-csail"],"acf":[],"_links":{"self":[{"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/posts\/3948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/comments?post=3948"}],"version-history":[{"count":1,"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/posts\/3948\/revisions"}],"predecessor-version":[{"id":4110,"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/posts\/3948\/revisions\/4110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/media\/4108"}],"wp:attachment":[{"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/media?parent=3948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/categories?post=3948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/go-dive.net\/en\/wp-json\/wp\/v2\/tags?post=3948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Broad Interest and Expert Support<\/h3>\n
![\"\"](\"http:\/\/go-dive.net\/wp-content\/uploads\/2025\/05\/AdobeStock_422714256.jpeg\")
<\/p>\nAI in Oncology Is Gaining Speed Everywhere<\/h3>\n
Barriers to Widespread Use<\/h3>\n
Looking Ahead<\/h3>\n